61

References

A. (2021, September 24). What Is Considered Tall in The Philippines? Colonel Height. Retrieved
June 21, 2022, from https://colonelheight.com/what-is-considered-tall-in-the-philippines/

Allen, R. H., Cwiak, C. A., & Kaunitz, A. M. (2013). Contraception in women over 40 years of
age. CMAJ: Canadian Medical Association journal = journal de l'Association medicale
canadienne, 185(7), 565–573. https://doi.org/10.1503/cmaj.121280

Can Birth Control Affect Libido and Sexual Drive? (n.d.). Virginia Beach OBGYN. Retrieved June
20, 2022, from https://www.virginiabeachobgyn.com/blog/can-birth-control-affect-libido-
and-sexual-drive/

Chawla, S., Gupta, V., Gour, N., & Goel, P. (2020). Determinants of injectable depot
medroxyprogesterone acetate contraception among women of reproductive age: A study
from Southern Haryana, India. Indian Journal of Community and Family Medicine, 6(2),
144. https://doi.org/10.4103/ijcfm.ijcfm_2_20

Centers for Disease Control and Prevention. (2022, June 3). Body Mass Index (BMI). Retrieved
June 20, 2022, from https://www.cdc.gov/healthyweight/assessing/bmi/index.html

Corporate Finance Institute. (2022, February 16). Weighted Mean. Retrieved June 20, 2021, from
https://corporatefinanceinstitute.com/resources/knowledge/other/weighted-mean/

DataStar, Inc. (n.d.). How to Interpret Standard Deviation and Standard Error in Survey Research |
GreenBook | GreenBook.org. GreenBook. Retrieved June 20, 2022, from
https://www.greenbook.org/marketing-research/how-to-interpret-standard-deviation-and-
standard-error-in-survey-research-03377

Department of Health. (2021, June). Anual Report 2020 Responsible Parenthood and Reproductive
Health Act of 2012. Tanya Mia M. Hisanan.
https://doh.gov.ph/sites/default/files/publications/7th%20Annual%20Report%20on%20the
%20Implementation%20of%20Responsible%20Parenting%20and%20Reproductive
%20Health%20Act%20of%202012%20%282020%29%2007052021.pdf

Department of Health. (2013). Implementing Rules and Regulations of Republic Act No. 10354
(The Responsible Parenthood and Reproductive Health Act of 2012).
https://doh.gov.ph/sites/default/files/policies_and_laws/RA10354_RPRHLawIRR1.pdf

Department of Health. (n.d.). What is an injectable? | Department of Health website. Retrieved

March 3, 2022, from https://doh.gov.ph/faqs/What-is-an-injectable
 62

Department of Health and Human Services , Body Mass Index: Considerations for Practitioners
(n.d.). Retrieved June 20, 2022, from
https://www.cdc.gov/obesity/downloads/bmiforpactitioners.pdf.

Diabetes Canada. (2022, June 20). Body Mass Index (BMI) Calculator. DiabetesCanadaWebsite.
Retrieved June 20, 2022, from https://www.diabetes.ca/managing-my-diabetes/tools---
resources/body-mass-index-(bmi) calculator#: %7E:text=Body%20Mass%20Index%20is
%20a, most%20adults%2018%2D65%20years.

DMPA Contraceptive Injection: Use and Coverage. (2020, January 28). KFF. Retrieved June 18,
2022, from https://www.kff.org/womens-health-policy/fact-sheet/dmpa-contraceptive-
injection-use-and-coverage/

Faculty of Sexual & Reproductive Healthcare. Overweight, obesity and contraception. FSRH,
2019. www.fsrh.org/documents/fsrh-clinical-guideline-overweight-obesity-and-
contraception/

Faculty of Sexual & Reproductive Healthcare. Progestogen-only injectable contraception. FSRH,

2014 (updated 2019). www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-
injectables-dec-2014
Faculty of Sexual & Reproductive Healthcare. U.K. medical eligibility criteria for contraceptive
use. FSRH, 2016. www.fsrh.org/ukmec/

Familydoctor.org editorial staff. (2020, September 11). Depo-Provera: An Injectable

Contraceptive. Familydoctor.Org. Retrieved February 25, 2022, from
https://familydoctor.org/depo-provera-an-injectable-contraceptive/

4.3 Frequency distribution. (2021, February 9). Statistics Canada. Retrieved June 20, 2022, from
https://www150.statcan.gc.ca/n1/edu/power-pouvoir/ch8/5214814-eng.htm

Herold, E. S. (1983). The Health Belief Model. Journal of School Health, 53(1), 19–21.
https://doi.org/10.1111/j.1746-1561.1983.tb04047.x

Jirakittidul, P., Somyaprasert, C., & Angsuwathana, S. (2019). Prevalence of Documented

Excessive Weight Gain Among Adolescent Girls and Young Women Using Depot
Medroxyprogesterone Acetate. Journal of Clinical Medicine Research, 11(5), 326–331.
https://doi.org/10.14740/jocmr3792
 63

Kaunitz, A. M., MD. (n.d.). The Global Library of Women’s Medicine’s. The Global Library of
Women’s Medicine’s Welfare of Women. Retrieved February 18, 2022, from
https://www.glowm.com/section-view/heading/The%20Importance%20of
%20Contraception/item/373

Kent State University. (2022, May 24). LibGuides: SPSS Tutorials: Home. Retrieved June 20,
2022, from https://libguides.library.kent.edu/SPSS

Mayniar T.E., L. D. (2017). Correlation between body mass index and leptin level on depo
medroxy progesterone acetate (DMPA) hormonal contraceptive users. Giornale Italiano Di
Ostetricia e Ginecologia, 39(6), 221. https://doi.org/10.11138/giog/2017.39.6.221
NICE. Endometriosis: diagnosis and management. NICE Guideline 73. NICE, 2017.
www.nice.org.uk/ng73

Messenger, B. (2019). Depot medroxyprogesterone acetate (DMPA) injections: an intermediate

option - bpacnz. Bpacnz. Retrieved June 21, 2022, from
https://bpac.org.nz/2021/contraception/depot.aspx

Nault, A. M., Peipert, J. F., Zhao, Q., Madden, T., & Secura, G. M. (2013). Validity of perceived
weight gain in women using long-acting reversible contraception and depot
medroxyprogesterone acetate. American journal of obstetrics and gynecology, 208(1),
48.e1–48.e488. https://doi.org/10.1016/j.ajog.2012.10.876

Nordqvist, C. (2022, January 20). Why BMI is inaccurate and misleading. Medical News Today.
Retrieved June 20, 2022, from https://www.medicalnewstoday.com/articles/265215

Oshodi, Y. A., Agbara, J. O., Ade Fashola, O. O., Akinlusi, F. M., Olalere, H. F., & Kuye, T. O.
(2019). Weight gain and menstrual abnormalities between users of Depo-provera and
Noristerat. International Journal of Reproduction, Contraception, Obstetrics and
Gynecology, 8(6), 2226. https://doi.org/10.18203/2320-1770.ijrcog20192131

Ozgoli, G., Sheikhan, Z., Dolatian, M., Simbar, M., Bakhtyari, M., & Nasiri, M. (2015).
Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate
(DMPA) and Cyclofem. Journal of reproduction & infertility, 16(2), 102–108.

Pisano G. (2016). Population Pyramids: Definition, Types, Stages. Retrieved from

https://study.com/academy/lesson/population-pyramids-definition-types-stages.html.

Shiferaw, M., Kassahun, W., & Zawdie, B. (2021). Anthropometric indices, blood pressure, and
lipid profile status among women using progestin-only contraceptives: a comparative
 64

cross-sectional study. BMC Women’s Health, 21(1). https://doi.org/10.1186/s12905-021-

01178-8

Silva Dos Santos, P. D. N., de Souza, A. L., Batista, G. A., Melhado-Kimura, V., de Lima, G. A.,
Bahamondes, L., & Fernandes, A. (2016). Binge eating and biochemical markers of
appetite in new users of the contraceptive depot medroxyprogesterone acetate. Archives of
Gynecology and Obstetrics, 294(6), 1331–1336. https://doi.org/10.1007/s00404-016-4192-9

Sims, J., Lutz, E., Wallace, K., Kassahun-Yimer, W., Ngwudike, C., & Shwayder, J. (2020a).
Depo-medroxyprogesterone Acetate, weight gain and Amenorrhea among obese adolescent
and adult women. The European Journal of Contraception & Reproductive Health Care,
25(1), 54–59. https://doi.org/10.1080/13625187.2019.1709963

Singata-Madliki, M., Carayon-Lefebvre d'Hellencourt, F., Lawrie, T. A., Balakrishna, Y., &
Hofmeyr, G. J. (2021). Effects of three contraceptive methods on depression and sexual
function: An ancillary study of the ECHO randomized trial. International journal of
gynaecology and obstetrics: the official organ of the International Federation of
Gynaecology and Obstetrics, 154(2), 256–262. https://doi.org/10.1002/ijgo.13594

Stacy, D. (2020, December 22). How Depo-Provera Can Be Used to Treat Endometriosis Pain.
Verywell Health. Retrieved June 6, 2022, from https://www.verywellhealth.com/depo-
provera-endometriosis-906705#:%7E:text=Depo%2DProvera%20has%20been
%20used,which%20leads%20to%20pain%20relief.

Statistics Canada. (2021, September 20). 4.3 Frequency distribution. Retrieved June 20, 2022, from
https://www150.statcan.gc.ca/n1/edu/power-pouvoir/ch8/5214814-eng.htm

Statistics Solutions. (2022, June 7). Paired Sample T-Test. Retrieved June 20, 2022, from
https://www.statisticssolutions.com/free-resources/directory-of-statistical-analyses/paired-
sample-t-test/

Veri, N., Mutiah, C., Dewita, D., Henniwati, H., Fazdria, F., Lajuna, L., & Salfiyadi, T. S. (2021).
The Effect of Duration of Use of Depomedroxyprogesterone Acetate on the Thickness of
the Vaginal Epithelium of Mice. Open Access Macedonian Journal of Medical Sciences,
9(A), 73–77. https://doi.org/10.3889/oamjms.2021.5574

Women’s Health Policy. (2020, January 28). DMPA Contraceptive Injection: Use and Coverage.
KFF. Retrieved October 16, 2021, from https://www.kff.org/womens-health-policy/fact-
sheet/dmpa-contraceptive-injection-use-and-coverage/
 65

World Bank Group. (2021). Population growth (annual %) - Philippines | Data. The World Bank.
Retrieved December 10, 2021, from https://data.worldbank.org/indicator/SP.POP.GROW?
locations=PH

World Health Organization. (2021, June 9). Obesity and overweight. Retrieved June 20, 2022, from
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Zerihun, M. F., Malik, T., Ferede, Y. M., Bekele, T., & Yeshaw, Y. (2019). Changes in body
weight and blood pressure among women using Depo-Provera injection in Northwest
Ethiopia. BMC Research Notes, 12(1). https://doi.org/10.1186/s13104-019-4555-y

Zainordin, N. A., Mohamed Shah, F. Z., & Abdul Ghani, R. (2019). Partial Adrenal Suppression
with Prolonged Use of Depo-Provera. Journal of Clinical and Health Sciences, 4(1), 64.
https://doi.org/10.24191/jchs.v4i1.7284
 66

APPENDICES
67
68
69
 70

APPENDIX B

HEALTH EFFECTS OF DEPOT-MEDROXYPROGESTERONE ACETATE AMONG

LONG-TERM ACCEPTORS IN BRGY. CARIDAD IBABA
ATIMONAN, QUEZON
Pangalan (Opsiyonal): ______

I. Demograpikong Impormasyon
Panuto: Punan ang patlang ng angkop na impormasyon o datos. Kung may pagpipilian, lagyan ng
tsek (/) ang kahon na tumutugma sa iyong sagot.
1. Edad:
15 - 25
26 – 35
36 – 45
46 at pataas
2. Gaano katagal nang nagpapaturok ng DMPA?
Dalawang (2) taon hanggang limang (5) taon
Limang (5) taon o higit pa
3. Timbang/ bigat: (kg) ____________

II. BMI (Body Mass Index)

1. Timbang
a. Bago magpaturok ng DMPA: _______kg
b. Kasalukuyang pagpapaturok ng DMPA: _______kg
2. Taas: _______ inches/centimeter

III. Epekto ng Depot-medroxyprogesterone Acetate sa pisikal at mental na aspeto

Panuto: Lagyan ng tsek(/) ang iyong sagot base sa dalas ng pagkakaramdam mo sa mga
sumusunod na epekto.
1 - Hindi kailanman 2 – Bihira 3 – Minsan 4–
Madalas 5 – Palagi
Mga posibleng epekto ng Depot- 5 4 3 2 1
 71

medroxyprogesterone Acetate sa
Hindi
pisikal na aspeto ng mga Palagi Madalas Minsan Bihira
kailanman
gumagamit nito
1. Amenorhea o pagkawala ng
buwanang regla
2. Spotting o bahagyang pagdurugo ng
puwerta hindi dahil sa regla
3. Labis na pag durugo
4. Pagtaas ng timbang
5. Kapansinpansin na paglaki ng tiyan
at braso

6. Pagbabago sa apetite

7. Pagkahilo
8. Fatigue o pagkapagod
9. Abdominal pain o pagsakit ng tiyan

10. Pagsakit ng suso

11. Pagsakit ng balakang

12. Pagsakit ng binti
13. Panlalagas ng buhok
14. Hot flashes o bigla at literal na
pag-init ng katawan na tumatagal
mula 30 segundo hanggang 10
minuto.

Mga posibleng epekto ng Depot-

1
medroxyprogesterone Acetate sa 5 4 3 2
Hindi
mental na aspeto ng mga Palagi Madalas Minsan Bihira
kailanman
gumagamit nito
1. Emotional distress o pagkabalisa.
 72

2. Insomnia o hirap matulog.

3. Pagkalungkot
4. Mababang kumpiyansa sa sarili
dahil sa pagbabagong naganap sa
katawan.
5. Nerbiyos o pagkakaba
6. Nagkakaroon ng pagbabago sa
libido o sex drive.
7. Nakararanas ng pagkalito.
8. Nakararanas ng labis na pagkasaya
o euphoria.

MARAMING SALAMAT PO!

 66

APPENDIX C

MAY KAALAMANG PAHINTULOT

Pamagat ng Pananaliksik: HEALTH EFFECTS OF DEPOT-

MEDROXYPROGESTERONE ACETAT AMONG LONG-TERM ACCEPTORS
IN BRGY. CARIDAD IBABA ATIMONAN, QUEZON

Mananaliksik: Allyssa Mae C. Laude

Bachelor of Science in Nursing 3A
SLSU – College of Allied Medicine

Magandang araw! Ako si Allyssa Mae C. Laude kasalukuyang nag-aaral sa

Southern Luzon State University at nasa ika-3 taon ng kursong Bachelor of Science in
Nursing. Nais kong ipag bigay alam sa inyo na ako ay kasalukuyang nagsasagawa ng
pag-aaral na pinamagatang “Health Effects of Depot-medroxyprogesterone Acetate
Among Long-term Acceptors in Brgy. Caridad Ibaba Atimonan, Quezon” at
malugod kong hinihingi ang inyong permiso upang maging isa sa mga tagatugon sa
aking sarbey.
Lahat ng pagkakakilanlan at impormasyong makukuha sa sarbey na ito ay
ituturing na probado at kompidensyal.
Lubos po akong umaasa sa inyong kooperasyon na lubhang makatutulong sa aking
pag- aaral. Maraming Salamat po!

Layunin ng pag-aaral
Layunin nitong alamin ang mga epektong pangkalusugan ng mga gumagamit ng
DMPA sa Brgy. Caridad Ibaba Atimonan, Quezon.

Pagiging Kompidensyal
Pananatilihin naming kompidensyal ang lahat ng inyong impormasyon sa abot
na pinapahintulot ng batas. Ang mga impormasyong makokolekta ay gagamitin lamang
para sa pag-aaral na ito. Tanging mga taong kasali sa pananaliksik na ito ang may
karapatang tumingin sa inyong palatanungan o “questionnaire”. Ang inyong pangalan at
iba pang detalye na makapagtuturo sa inyo ay hindi ihahayag kapag napag-usapan ang
survey o mailathala ang mga resulta nito.

Panganib
Walang malaking panganib sa pag-aaral na ito.
 67

Karapatang tumanggi
Kayo po ay malaya na sumali o hindi sa survey na ito at makakatanggap pa rin
ng parehong pangangalaga anuman ang inyong maging desisyon. Kung nagpasya po
kayong sumali sa pananaliksik na ito, kayo po ay malayang magpalit ng isipan kahit
anong oras para sa anumang kadahilanan. Walang parusa para sa pagtanggi ng inyong
partisipasyon at maaari mong tanggihan nang hindi kinakailangang magbigay ng
dahilan.

Sertipiko ng Pahintulot
Nabasa ko ang kasulatang ito o binasa at naipaliwanag ang tungkol sa mga
layunin ng pananaliskik, mga posibleng panganib at mga benepisyo nito. Ako ay
nakapagtanong tungkol sa pananaliksik at nasagot naman ang aking mga katanungan.
Nauunawaan ko na maaari kong tanggihan ang paglahok sa pananaliksik na ito. Ako ay
pumapayag maging isa sa mga kalahok ng pananaliksik na ito.

_______________________________________
Pangalan at Lagda ng Sumagot
__________________
Petsa

Pahayag ng Taong Nagsasagawa ng Pagkuha ng Pahintulot

Aking binasa nang tama ang kasulatan na ito sa potensyal na kalahok. Aking
pinagtitibay na siya ay binigyan ko ng pagkakataon na magtanong tungkol sa pagsusuri
at lahat ng kanyang mga tanong ay aking nasagot sa abot ng aking makakaya. Aking
pinagtitibay na ang taong kalahok ay hindi pinilit na magbigay ng pahintulot at ang
kanyang pahintulot ay binigay nang malaya at boluntaryo.
Ang kopya ng Kasulatan ng Pahintulot ay ibinigay sa kalahok.

Allyssa Mae C. Laude

Pangalan at Lagda ng Kumuha ng Pahintulot
 68

APPENDIX D
Computation

Paired Sample T-Test between the body mass index of respondents before and after using
depo-medroxyprogesterone acetate.

Descriptive Statistics
------------------------------------------------------------------------
-------------------
Difference N Lower CI* Mean Upper CI*
StdDev SE_Mean
------------------------------------------------------------------------
-------------------
BMI after DPMA – BMI before DPMA 33 1.62 2.75 3.88
3.18 0.5540
------------------------------------------------------------------------
-------------------
* At 95% Confidence Level.

Paired Sample t-Test, h0: mean diff = 0

---------------------------------------------------------
Difference DF t Value Pr(>|t|)
---------------------------------------------------------
BMI after DPMA – BMI before DPMA 32 4.97 <0.0001**
---------------------------------------------------------
**highly significant at p  0.01

Paired Sample T-Test between the weight (kg) of respondents before and after using
depo-medroxyprogesterone acetate.

Descriptive Statistics
------------------------------------------------------------------------
-----------------------------------
Difference N Lower CI*
Mean Upper CI* StdDev SE_Mean
------------------------------------------------------------------------
-----------------------------------
Weight after using DPMA – Weight before using DPMA 33 0.8283
3.58 6.34 7.77 1.35
------------------------------------------------------------------------
-----------------------------------
* At 95% Confidence Level.

Paired Sample t-Test, h0: mean diff = 0

------------------------------------------------------------------------
--------
Difference DF t Value
Pr(>|t|)
------------------------------------------------------------------------
--------
Weight after using DPMA – Weight before using DPMA 32 2.65
0.0124*
 69

------------------------------------------------------------------------
--------
*significant at p  0.05

Test of difference of the body mass index before using DPMA when grouped according

to age using One-Way Analysis of Variance (ANOVA)

ANOVA TABLE
Response Variable: BMI before using DPMA
---------------------------------------------------------
Source DF Sum of Square Mean Square F Value Pr(> F)
---------------------------------------------------------
Age 4 90.8658 22.7165 0.86 0.4977 ns
Error 28 736.3093 26.2968
Total 32 827.1752
---------------------------------------------------------

Summary Statistics
-------------------------------------
CV(%) BMI before using DPMA Mean
-------------------------------------
21.53 23.82
-------------------------------------

Table of Means
-----------------------------------------
AGE BMI before using DPMA Means
-----------------------------------------
15 - 25 19.90
26 - 35 23.14
36 - 45 23.99
46 pataas 26.98
-----------------------------------------

Test of difference of the body mass index after using DPMA when grouped according to

age using One-Way Analysis of Variance (ANOVA).

ANOVA TABLE
Response Variable: BMI after using DPMA
---------------------------------------------------------
Source DF Sum of Square Mean Square F Value Pr(> F)
---------------------------------------------------------
Age 4 199.7857 49.9464 2.58 0.0587 ns
Error 28 541.2492 19.3303
Total 32 741.0349
---------------------------------------------------------

Summary Statistics
-------------------------------
CV(%) Kasalukuyang.BMI Mean
-------------------------------
16.55 26.57
-------------------------------
 70

Table of Means
------------------------------------
AGE Kasalukuyang.BMI Means
------------------------------------
15 - 25 21.20
26 - 35 24.90
26 -35 22.90
36 - 45 27.31
46 pataas 31.30
------------------------------------

Test of difference of the body mass index after using DPMA when grouped according to

the duration of use of DPMA using One-Way Analysis of Variance (ANOVA).

ANOVA TABLE
Response Variable: BMI after using DPMA
------------------------------------------------------------------------
-------------------
Source DF Sum of Square Mean
Square F Value Pr(> F)
------------------------------------------------------------------------
-------------------
Duration of use of DPMA 1 49.7565
49.7565 2.23 0.1453 ns
Error 31 691.2785
22.2993
Total 32 741.0349
------------------------------------------------------------------------
-------------------

Summary Statistics
-----------------------------------
CV(%) BMI after using DPMA Mean
-----------------------------------
17.77 26.57
-----------------------------------

Table of Means
---------------------------------------------------------------------
Duration of use of DPMA BMI after using DPMA Means
---------------------------------------------------------------------
Dalawang (2) taon hanggang limang (5) taon 25.14
Limang (5) taon o higit pa 27.63
---------------------------------------------------------------------

Test of difference of the body mass index before using DPMA when grouped according
to the weight before using DPMA using One-Way Analysis of Variance (ANOVA)

ANOVA TABLE
Response Variable: BMI before using DPMA
------------------------------------------------------------------------
---------------
 71

Source DF Sum of Square Mean Square

F Value Pr(> F)
------------------------------------------------------------------------
---------------
Weight before using DPMA 5 346.5039 69.3008
3.89 0.0087 **
Error 27 480.6713 17.8026
Total 32 827.1752
------------------------------------------------------------------------
---------------
**highly significant at p  0.01

Summary Statistics
------------------------------------
CV(%) BMI before using DPMA Mean
------------------------------------
17.71 23.82
------------------------------------

Pairwise Mean Comparison of Weight before using DPMA

Tukeys's Honest Significant Difference (HSD) Test

Alpha 0.05
Error Degrees of Freedom 27
Error Mean Square 17.8026
Critical Value 4.3329
Test Statistics 10.1266
Harmonic Mean of Cell Sizes 3.2593

Summary of the Result:

-------------------------------------------------------------
Weight before using DPMA means group
-------------------------------------------------------------
30 to 40 kg 24.35 ab
41 to 50 kg 19.96 b
51 to 60 kg 24.24 ab
61 to 70 kg 28.43 ab
71 to 80 kg 26.90 ab
81 to 90 kg 30.45 a
-------------------------------------------------------------
Mean values followed by different letters in the same column are
significantly different at p  0.01 on Tukey’s Honest Significant
Difference Test
 72

Test of difference of the body mass index after using DPMA when grouped according to
the weight after using DPMA using One-Way Analysis of Variance (ANOVA)

ANOVA TABLE
Response Variable: BMI after using DPMA
------------------------------------------------------------------------
----------------------------
Source DF Sum of Square
Mean Square F Value Pr(> F)
------------------------------------------------------------------------
----------------------------
Weight after using DPMA 5 513.4567
102.6913 12.18 <0.0001 **
Error 27 227.5782
8.4288
Total 32 741.0349
------------------------------------------------------------------------
----------------------------
**highly significant at p  0.01

Summary Statistics
------------------------------------
CV(%) BMI after using DPMA Mean
------------------------------------
10.93 26.57
------------------------------------

Pairwise Mean Comparison of Weight after using DPMA

Tukeys's Honest Significant Difference (HSD) Test

Alpha 0.05
Error Degrees of Freedom 27
Error Mean Square 8.4288
Critical Value 4.3329
Test Statistics 8.6551
Harmonic Mean of Cell Sizes 2.1125

Summary of the Result:

------------------------------------------------------------------------
--
Weight after using DPMA means group
------------------------------------------------------------------------
--
30 to 40 kg 26.90 bc
41 to 50 kg 20.27 c
51 to 60 kg 24.52 bc
61 to 70 kg 28.58 abc
71 to 80 kg 32.00 ab
81 to 90 kg 35.90 a
------------------------------------------------------------------------
--
Mean values followed by different letters in the same column are
significantly different at p  0.01 on Tukey’s Honest Significant
Difference Test
 73

Test of difference of the body mass index before using DPMA when grouped according

to height using One-Way Analysis of Variance (ANOVA)

ANOVA TABLE
Response Variable: BMI before using DPMA
------------------------------------------------------------------
Source DF Sum of Square Mean Square F Value Pr(> F)
------------------------------------------------------------------
Height 9 259.0009 28.7779 1.16 0.3614 ns
Error 23 568.1742 24.7032
Total 32 827.1752
------------------------------------------------------------------

Summary Statistics
-------------------------------
CV(%) BMI before using DPMA
-------------------------------
20.86 23.82
-------------------------------

Table of Means
-------------------------------------
Height BMI before using DPMA
-------------------------------------
141 cm or 4'8 20.90
144.78 cm or 4'9 26.20
149.86 cm or 4'11 28.30
152.40 cm or 5' 21.90
154.94 cm or 5'1 22.26
157.48 cm or 5'2 22.49
160.02 cm or 5'3 29.12
165.1 cm or 5'5 23.60
167.64 cm or 5'6 19.90
-------------------------------------
Test of difference of the body mass index after using DPMA when grouped according to
height using One-Way Analysis of Variance (ANOVA)

ANOVA TABLE
Response Variable: BMI after using DPMA
------------------------------------------------------------------
Source DF Sum of Square Mean Square F Value Pr(> F)
------------------------------------------------------------------
Height 9 90.2168 10.0241 0.35 0.9453 ns
Error 23 650.8182 28.2964
Total 32 741.0349
------------------------------------------------------------------

Summary Statistics
------------------------------------
CV(%) BMI after using DPMA Mean
------------------------------------
20.02 26.57
------------------------------------
 74

Table of Means
-------------------------------------------------
Height BMI after using DPMA Means
-------------------------------------------------
141 cm or 4'8 24.85
144.78 cm or 4'9 26.90
149.86 cm or 4'11 29.20
152.40 cm or 5' 25.80
154.94 cm or 5'1 25.81
157.48 cm or 5'2 26.05
160.02 cm or 5'3 29.00
165.1 cm or 5'5 28.05
167.64 cm or 5'6 21.20
-------------------------------------------------